MARKET WIRETradingView • 21h ago
PRF Technologies Ltd. Estimates – NASDAQ:PRFXTradingView report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
Why PRFX Stock dropped -2.68% Today — RQD Quant Desk Flash
$0.73 -2.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.73
PRF Technologies Ltd. (PRFX) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $2.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PRFX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PRFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, PRF Technologies Ltd. (NASDAQ: PRFX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.73 (-2.68% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRFX ranks #707 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PRFX compare to DCOY and HCWB in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRFX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, DCOY (Decoy Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and HCWB (HCW Biologics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M). Among the 5-stock peer group, PRFX leads on earnings multiple (N/A) while PRFX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PRFX?
▼
Per PRFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801834), PRF Technologies Ltd. generated $17.0K in revenue (-100.0% YoY), -$5.0M in net income, and -$4.0M in free cash flow against $12.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.73 (-0.67%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRFX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY PRFX SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.82-11% Next Q
41
Q2 (-2Q)Grade E$0.73+4.1% Next Q
38
Q3 (-1Q)Grade E$0.76-3.9% Next Q
36
CurrentGrade E$0.73-8.9% Hist 90D α
33
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PRFX Turnaround Squeeze
While PRFX currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.88) and Max Pain ($0.77) forces dealer call-delta covering toward $8.35.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRFX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRFX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PRFX Stock dropped -2.68% Today — RQD Quant Desk Flash
PRF Technologies Ltd. (PRFX) dropped -2.68% to $0.73, trading at 2% of its 52-week range ($0.69 – $7.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.69 – $7.95) with RSI-14 at 37.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.73 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 0% gross margin and $0 annual free cash flow.
Live PRFX Headlines & Catalysts
MARKET WIREYahoo Finance UK • 1d ago
PRF Technologies Ltd. (PRFX) Seasonal returns chartYahoo Finance UK report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
PRF Technologies Highlights $11 Million Cash, Phase 2 OcuRing™-K Trial Plans and GridFeed AI Data Center StrategyThe Globe and Mail report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMoomoo • 1d ago
Press Release: PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing(TM)-K and GridFeed(TM) Opportunity in AI Data Center PowerMoomoo report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com India • 1d ago
PRF Technologies reports $11M cash, plans phase 2 trial By Investing.comInvesting.com India report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center PowerGlobeNewswire report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREChartMill • 3d ago
Postmarket Movers: After-Hours Gainers and LosersAfter-hours movers: INOVIO jumped 283.0% and Glucotrack dropped 57.19%, among the largest postmarket gainers and losers.
RISK WATCHBenzinga • 11d ago
PRF Technologies Reports Cash Of ~$11M As Of Sept. 30; Plans To Initiate Enrollment In Its U.S. Multi-Center Clinical Study Of OcuRing-K; Intendws To Estabish GridFeed vAs Standalone SubsidiaryPRF Technologies Ltd. (NASDAQ:PRFX) ("PRF", "PRF Technologies" or the "Company") today issued a Letter to Shareholders from Efraim Cohen-Arazi, Interim Chief Executive Officer.Nine Months 2026
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRFX)
- ✓Walkthrough of PRFX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PRFX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.94%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.75H $0.75L $0.73C $0.73VOL 58.6K
RES: $1.25SUP: $0.64SMA50: $0.88SMA200: $1.79
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PRFX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -100.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on PRFX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PRFX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRFX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRFX)
Health Care Rank #707 of 1015
⚔️ DCOY vs PRFX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PRFX vs. DCOY, HCWB, APVO, JUNS)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, PRF Technologies Ltd. (PRFX) ranks #707 by composite RQD confidence (33/100, grade E) and #981 by equity capitalization ($2.6M). Within this direct 5-issuer industry benchmark cohort, PRFX leads on earnings valuation at N/A trailing P/E, while PRFX leads on capital efficiency and profitability with -35.0% ROIC and -30.0% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with PRFX at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRFX
ACTIVE
PRF Technologies Ltd. | E | 33/100 | — | -30.0% | -35.0% | -2.68% | $2.6M | Benchmark Subject |
| DCOY Decoy Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -13.01% | $2.6M | /dcoy-vs-prfx → |
| HCWB HCW Biologics Inc. | E | 23/100 | — | 20.0% | -35.0% | -6.78% | $2.5M | /hcwb-vs-prfx → |
| APVO Aptevo Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -1.47% | $2.4M | /apvo-vs-prfx → |
| JUNS Jupiter Neurosciences Inc. | E | 29/100 | — | 80.6% | -35.0% | -13.50% | $2.7M | /juns-vs-prfx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001801834 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), PRF Technologies Ltd. (PRFX) reported GAAP revenue of $17.0K (-100.0% vs. FY2024 revenue of $41.1M , and -99.9% cumulative change since FY2023) , GAAP net income of -$5.0M, operating cash flow of -$4.0M, and free cash flow of -$4.0M (+68.7% YoY). On the balance sheet, PRFX closed FY2025 with $12.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $17.0K | -$5.0M | -$4.0M | -$4.0M | $12.0M | — |
| FY2024 (FY) | 2024-12-31 | $41.1M | -$14.6M | -$12.6M | -$12.6M | $4.5M | — |
| FY2023 (FY) | 2023-12-31 | $26.8M | -$9.3M | -$6.7M | -$6.7M | — | — |
3. PRFX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PRFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, PRF Technologies Ltd. (NASDAQ: PRFX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.73 (-2.68% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRFX ranks #707 in composite RQD confidence.
How does PRFX compare to DCOY and HCWB in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRFX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, DCOY (Decoy Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and HCWB (HCW Biologics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M). Among the 5-stock peer group, PRFX leads on earnings multiple (N/A) while PRFX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PRFX?
Per PRFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801834), PRF Technologies Ltd. generated $17.0K in revenue (-100.0% YoY), -$5.0M in net income, and -$4.0M in free cash flow against $12.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PRFX trading relative to its 50-day, 200-day, and 52-week technical levels?
PRFX last traded at $0.73 (-2.68% on volume of 58,596 shares), positioning the stock -17.05% below its 50-day simple moving average ($0.88) and -59.22% below its 200-day simple moving average ($1.79). Across its 52-week range of $0.69 to $7.95, PRFX sits at the 0.6% percentile with a 14-day RSI of 37.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.82).
ROARABLE RATING BRIEF • RQD 33/100 (E)
✓ SEC XBRL & RQD VERIFIED
PRFX — PRF Technologies Ltd.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
PRF Technologies Ltd. (PRFX) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.73 (-2.68% 1D, market capitalization $2.6M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
PRF Technologies Ltd. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. The source data identifies the company's product and customer base only through its news items, which reference an OcuRing™-K trial and a GridFeed™ strategy for AI data center power, but does not describe revenue sources or customers. Revenue is reported as — in each annual period.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PRF Technologies Ltd. (PRFX) reported $17.0K in annual revenue (up from $41.1M in FY2024, -100.0% YoY) and -$5.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($26.8M revenue, -$9.3M net income) through FY2025, PRFX scaled operating cash flow to -$4.0M and free cash flow to -$4.0M, backed by $12.0M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.69 – $7.95 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PRFX carries a macro regime beta of 1.00 and gross margin of -30.0%.
- Key Question #1: Can PRFX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $17.0K and free cash flow of -$4.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is PRFX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
PRFX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for PRF Technologies Ltd. (PRFX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 21h ago
PRF Technologies Ltd. Estimates – NASDAQ:PRFX TradingView report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
PRF Technologies Ltd. (PRFX) Seasonal returns chart Yahoo Finance UK report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
PRF Technologies Highlights $11 Million Cash, Phase 2 OcuRing™-K Trial Plans and GridFeed AI Data Center Strategy The Globe and Mail report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
Press Release: PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing(TM)-K and GridFeed(TM) Opportunity in AI Data Center Power Moomoo report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com India • 1d ago
PRF Technologies reports $11M cash, plans phase 2 trial By Investing.com Investing.com India report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Friday's After-Market Session Benzinga report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center Power GlobeNewswire report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 3d ago
Postmarket Movers: After-Hours Gainers and Losers After-hours movers: INOVIO jumped 283.0% and Glucotrack dropped 57.19%, among the largest postmarket gainers and losers.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PRFX Bull vs. Bear Conversation Board — What's Your Call at $0.73?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRFX 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $0.96 (+31.5%)
📌 Pinned Debate Reported cash of $11 million in news headlines, plus a Phase 2 trial plan, could support runway if the figure is confirmed.
Long PRFX at $0.73 targeting $0.96. Reported cash of $11 million in news headlines, plus a Phase 2 trial plan, could support runway if the figure is confirmed.. Institutional whale score is 6/20 and the risk/reward vs. the $0.69 52-week low is skewed heavily in favor of bulls.
RetailWhale_TX 🐂 BULL
Both sides have a point here — PRFX's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $0.62 (-15.1%)
Spot @ $0.73 ROIC of -35%, zero revenue in each reported period, and an E-grade RQD score of 34 indicate severe forensic and cash-generation risk.
Fading this rally in PRFX at $0.73. ROIC of -35%, zero revenue in each reported period, and an E-grade RQD score of 34 indicate severe forensic and cash-generation risk.. With a beta of 1.0 and the stock sitting at $0.73 (52-wk range $0.69–$7.95), the easy multiple expansion is already priced in.